1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 7
2 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications – Introduction 8
2.1 GBI Research Report Guidance 9
3 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications – Oncology 10
3.1 Comparative Analysis of Late Stage Pipeline Molecules in NSCLC 10
3.1.1 Overview 10
3.1.2 Opportunity and Unmet Need 10
3.1.3 Strategic Pipeline Assessment 10
3.1.4 Comparative Analysis of Late Stage Pipeline Molecules Based on Major Characteristics 13
3.1.5 Promising Drugs under Clinical Development 15
3.1.6 Other Promising Drugs under Clinical Development 18
3.2 Comparative Analysis of Late Stage Pipeline Molecules in Colorectal Cancer 19
3.2.1 Overview 19
3.2.2 Opportunity and Unmet Need 19
3.2.3 Strategic Pipeline Assessment 21
3.2.4 Trends in Colorectal Cancer Pipeline 23
3.2.5 Comparative Analysis Based on Major Characteristics 24
3.2.6 Promising Drugs Under Clinical Development 25
3.3 Comparative Analysis of Late Stage Pipeline Molecules in Breast Cancer 31
3.3.1 Overview 31
3.3.2 Opportunity and Unmet Need 31
3.3.3 Strategic Pipeline Assessment 31
3.3.4 Comparative Analysis Based on Major Characteristics 34
3.3.5 Promising Drugs under Clinical Development 35
3.4 Comparative Analysis of Late Stage Pipeline Molecules in Prostate Cancer 37
3.4.1 Overview 37
3.4.2 Opportunity and Unmet Need 37
3.4.3 Strategic Pipeline Assessment 40
3.4.4 Trends in Prostate Cancer Pipeline 42
3.4.5 Comparative Analysis Based on Major Characteristics 43
3.4.6 Promising Drugs under Clinical Development 44
4 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications – Metabolic Disorders 50
4.1 Comparative Analysis of Late Stage Pipeline Molecules in Type II Diabetes 50
4.1.1 Overview 50
4.1.2 Opportunity and Unmet Need 50
4.1.3 Strategic Pipeline Assessment 51
4.1.4 Comparative Analysis Based on Major Characteristics 53
4.1.5 Promising Drugs under Clinical Development 54
5 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications – Respiratory Diseases 58
5.1 Comparative Analysis of Late Stage Pipeline Molecules in COPD 58
5.1.1 Overview 58
5.1.2 Opportunity and Unmet Need 58
5.1.3 Strategic Pipeline Assessment 59
5.1.4 Comparative Analysis Based on Major Characteristics 61
5.1.5 Promising Drugs under Clinical Development 62
6 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications – Musculoskeletal 66
6.1 Comparative Analysis of Late Stage Pipeline Molecules in Rheumatoid Arthritis 66
6.1.1 Overview 66
6.1.2 Opportunity and Unmet Need 66
6.1.3 Strategic Pipeline Assessment 67
6.1.4 Comparative Analysis Based on Major Characteristics 69
6.1.5 Promising Drugs under Clinical Development 70
7 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications – Central Nervous System 73
7.1 Comparative Analysis of Late Stage Pipeline Molecules in Epilepsy 73
7.1.1 Overview 73
7.1.2 Opportunity and Unmet Need 73
7.1.3 Strategic Pipeline Assessment 74
7.1.4 Comparative Analysis Based on Major Characteristics 76
7.1.5 Promising Drugs under Clinical Development 77
7.2 Comparative Analysis of Late Stage Pipeline Molecules in Multiple Sclerosis 82
7.2.1 Overview 82
7.2.2 Opportunity and Unmet Need 82
7.2.3 Strategic Pipeline Assessment 83
7.2.4 Comparative Analysis Based on Major Characteristics 85
7.2.5 Promising Drugs under Clinical Development 86
7.3 Comparative Analysis of Late Stage Pipeline Molecules in Major Depressive Disorder 88
7.3.1 Overview 88
7.3.2 Opportunity and Unmet Need 88
7.3.3 Strategic Pipeline Assessment 89
7.3.4 Comparative Analysis Based on Major Characteristics 91
7.3.5 Promising Drugs under Clinical Development 92
8 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications – Immunology 94
8.1 Comparative Analysis of Late Stage Pipeline Molecules in Crohn’s Disease 94
8.1.1 Overview 94
8.1.2 Opportunity and Unmet Need 94
8.1.3 Strategic Pipeline Assessment 95
8.1.4 Comparative Analysis Based on Major Characteristics 97
8.1.5 Promising Drugs under Clinical Development 98
9 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications – Cardiovascular 102
9.1 Comparative Analysis of Late Stage Pipeline Molecules in Hypertension 102
9.1.1 Overview 102
9.1.2 Opportunity and Unmet Need 102
9.1.3 Strategic Pipeline Assessment 103
9.1.4 Comparative Analysis Based on Major Characteristics 105
9.1.5 Promising Drugs under Clinical Development 106
10 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications – Infectious Disease 107
10.1 Comparative Analysis of Late Stage Pipeline Molecules in HIV/ AIDS 107
10.1.1 Overview 107
10.1.2 Opportunity and Unmet Need 107
10.1.3 Strategic Pipeline Assessment 108
10.1.4 Comparative Analysis Based on Major Characteristics 110
10.1.5 Promising Drugs under Clinical Development 111
11 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications – Gastrointestinal Diseases 117
11.1 Comparative Analysis of Late Stage Pipeline Molecules in Ulcerative Colitis 117
11.1.1 Overview 117
11.1.2 Opportunity and Unmet Need 117
11.1.3 Strategic Pipeline Assessment 118
11.1.4 Comparative Analysis Based on Major Characteristics 120
11.1.5 Promising Drugs under Clinical Development 121
12 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications – Conclusion 123
12.1 Oncology Pipeline Holds Most Prominence for Market Players 123
12.2 Colorectal Cancer Most Noteworthy Indications With Respect To Phase III Activity 124
12.3 An Average Of 50% Unmet Need Common in Oncology Therapeutics Followed By RA 125
12.4 Kinase Inhibitors – Most Important First-In-class Drug 126
12.5 Receptor Tyrosine Kinase and Vaccines Are Major Promising Class Based On Sales Forecast for Oncology 127
13 Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Appendix 128
13.1 Marketed Definitions 128
13.2 Abbreviations 128
13.3 Research Methodology 130
13.3.1 Coverage 130
13.3.2 Secondary Research 130
13.3.3 Primary Research 131
13.3.4 Expert Panel Validation 131
13.4 Contact Us 131
13.5 Disclaimer 131
13.6 Sources 132